Losartan Potassium Tablet, Film Coated
Product Images NDC 70518-4289

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 70518-4289). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

This is a description for Losartan Potassium 100 mg tablet. The quantity is 30 tablets. It is a prescription medication with an NDC number provided. The medication is manufactured by Macleods Pharma in Baddi, India. The storage instructions recommend keeping it at 20-25°C, with excursions permitted to 15-30°C. The directions for use are available in the package insert. It has been repackaged by Remedy Repack Inc. in Indiana, PA.*

FDA Label Image

Fig.3 (Losartan Figure No 3)

This is a tabular presentation likely showing results from a study or clinical trial. It includes data on participants' demographics (age, gender, race), medical conditions (ISH - possibly hypertension, Diabetes, History of CVD), and treatment effectiveness (Primary Composite - possibly related to stroke) comparing Losartan and Atenolol. The table contains information such as the number of events, event rates, and hazard ratios with their confidence intervals. There seems to be a comparison between different categories within each variable (e.g., age groups, genders) and potentially the impact of treatments on outcomes.*

FDA Label Image

Fig.1 (Losartan Figure1)

This appears to be a data table showing the percentage of patients reaching the primary endpoint over time for two different treatments, Losartan Potassium and Atenolol. An adjusted risk reduction of 13% is mentioned. The table spans study months from 12 to 68.*

FDA Label Image

Fig.2 (Losartan Figure2)

This text provides information on a comparison between Atenolol and Losartan Potassium in terms of adjusted risk reduction for fatal or non-fatal strokes. The study shows a 26% risk reduction with a p-value of 0.001 over a period of 60 study months.*

FDA Label Image

Fig.4 (Losartan Figure4)

This is not readable.*

FDA Label Image

Str (Losartan Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.